Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

US stock futures edged lower on Friday as investors digested a highly anticipated monthly jobs report and Amazon's (AMZN) ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The S&P 500 ( ^GSPC) nudged up 0.1%, while the tech-heavy Nasdaq Composite ( ^IXIC) added roughly 0.3%. The Dow Jones Industrial Average ( ^DJI) traded flat on the heels of a mixed day for stocks on ...

Novo Nordisk's strong stock performance and analysts' high revenue projections have set a high bar for the company's future performance. Meeting these expectations may become challenging ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group said on Thursday after business leaders, including CEO of obesity drugmaker ...

Moderna and Novo Nordisk are once again in the bad books ... in COVID-19 vaccine trial Moderna’s case centered on a 2023 meeting attended by 56 healthcare professionals from 20 countries to ...